BioCentury | Oct 9, 2020
Deals

Oct. 8 Quick Takes: Kronos ready for NASDAQ debut; plus Sensei, TCRyption, Jazz, Pfizer-Opko and Moderna

...and Opko Health Inc. (NASDAQ:OPK) said once-weekly somatrogon met its primary endpoint vs. once-daily Genotropin somatropin...
BioCentury | Sep 5, 2020
Product Development

Sept. 4 Quick Takes: HiFiBiO in second cancer deal with Gilead; plus Bridgewest-Pfizer, Amarin, Intercept, Santhera-Idorsia, CMS, Ascendis

...BLA for TransCon hGH lonapegsomatropin to treat pediatric growth hormone deficiency. The long-acting prodrug of somatropin...
BioCentury | Jul 27, 2018
Regulation

Getting into action

...pathway. These include naturally sourced products such as hyaluronidase and recombinant proteins such as Omnitrope somatropin...
BioCentury | Sep 22, 2017
Clinical News

Versartis falls on Phase III GHD miss

...trading Thursday after reporting that somavaratan (VRS-317) missed the primary endpoint of non-inferiority to Genotropin somatropin...
BioCentury | Sep 22, 2017
Clinical News

Versartis' somavaratan misses in Phase III for pediatric GHD

...Versartis Inc. (NASDAQ:VSAR) said somavaratan (VRS-317) missed the primary endpoint of non-inferiority to Genotropin somatropin in...
BioCentury | Apr 7, 2017
Strategy

Pushing for progress in Prader-Willi

...NYSE:NVO) Growth hormone deficiency Marketed Genotropin somatropin Pfizer Inc. (NYSE:PFE) Growth hormone deficiency Marketed Omnitrope somatropin...
BioCentury | Jan 5, 2017
Clinical News

hGH-CTP: Ph III started

...an open-label, U.S. Phase III trial to evaluate once-weekly subcutaneous hGH-CTP vs. once-daily subcutaneous Genotropin somatropin...
BioCentury | Nov 21, 2016
Strategy

LG’s biotech legacy

...antibiotic in Factive gemifloxacin, and the first Korean company with a globally approved biologic, Valtropin somatropin...
BioCentury | Sep 26, 2016
Clinical News

GX-H9: Interim Phase II data

...IGF-1 ) levels by 101.3 ng/mL vs. 109.1 ng/mL for once-daily 6 ug/kg Genotropin somatropin...
BioCentury | Sep 26, 2016
Clinical News

GX-H9: Phase II data

...with growth hormone deficiency showed that subcutaneous GX-H9 was well tolerated. Patients received once-daily Genotropin somatropin...
Items per page:
1 - 10 of 216